Major Ingredients

Each vial (25 ml) contains Doxorubicin Hydrochloride USP 50 mg Sterile Injectable Solution for Intravenous use.

Major Functionality

It is indicated for the treatment of acute lymphoblastic & myeloblastic leukemia, Hodgkin & non-Hodgkin lymphoma (NHL), metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcoma, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma & metastatic bronchogenic carcinoma.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.